Nick is a co-founder and CEO of Accunea Ltd, a medical device company with real time diagnostic monitoring products for organ transplantation.
Nick has always been interested in genetics since his youth, in particular how variations in genes can lead to diseases and the potential to find solutions.
Nick studied at some of the best universities in the world, including Oxford, Harvard and Warwick and it would have been easy for him to stay in the academic sector and forge a steady and successful career. However, he had developed a great idea in the years prior and decided to take some risk to create a start-up.
He founded and became CEO of a company called ‘Novolytics Limited’, formed specifically to help overcome the problems of antibacterial resistance.
He faced big challenges, including how the concept had no proven link to market. Financing was difficult and there were regulatory issues. However, the company finally received grant-funding, found an angel investor, and ultimately became successful.
Skip forward to 2018, Nick has co-founded another company – Accunea. This company developed after Nick met Robert Learney at an organisation called Panacea Innovation, which brings in mentors for companies.
Nick’s motivation with Accunea is in the company’s potential to help patients get off organ-donor waiting lists and provide them with fully functioning organ transplants.
Accunea is currently at prototype stage, and having proven the technology in pig kidneys, the company is now positioning itself to prove it for humans.
With patented technology, spun out from Imperial College, Accunea is unique because there is no direct competition, with the bigger more-established players specialising in point of care technologies which are not real time, have expensive running costs, are time consuming, and more complex.
Nick believes because of this, Accunea will be a prime acquisition target for some of these larger companies, particularly once the technology receives its CE marking and progresses to human trials and beyond.
To learn more about Accunea, please click here.
